San Mateo, CA, United States of America

Ash A Alizadeh

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 78(Granted Patents)


Company Filing History:

goldMedal2 out of 832,680 
Other
 patents

Years Active: 2008-2009

where 'Filed Patents' based on already Granted Patents

2 patents (USPTO):

Title: Innovator Spotlight: Ash A Alizadeh

Introduction:

Ash A Alizadeh, based in San Mateo, California, is a notable figure in the field of medical innovation, particularly in the realm of oncology. With a focus on improving the classification and treatment of diffuse large B-cell lymphoma (DLBCL), Alizadeh's contributions to science and medicine have resulted in significant advancements through her patented innovations.

Latest Patents:

Alizadeh holds two patents that showcase her expertise in classifying patients with DLBCL based on gene expression. Her latest patents include methods and kits designed to measure gene expression levels using real-time quantitative RT-PCR. By correlating the expression values of various genes in tumor samples to reference values from other DLBCL patients, Alizadeh’s methods enable the stratification of patients into distinct classification groups. Importantly, these innovations also provide tools to predict overall patient survival, reflecting her commitment to enhancing patient outcomes through targeted therapeutic strategies.

Career Highlights:

Throughout her career, Ash A Alizadeh has made significant contributions to the field of cancer research. Her innovative work has not only led to her patents but has also established her as a leading expert in the classification of complex diseases. Her dedication to research is evident in her focus on developing practical applications of genetic information for clinical use.

Collaborations:

Alizadeh has worked alongside esteemed colleagues Ronald Levy and Mark A Wechser. Their collaborative efforts emphasize the importance of teamwork in advancing scientific discovery and enhancing the efficacy of cancer treatments. Together, they have contributed to the development of methodologies that improve the understanding of DLBCL and patient management strategies.

Conclusion:

Ash A Alizadeh represents a powerful force in medical innovation, specifically in oncology. Her patents and collaborative efforts reflect a deep commitment to enhancing patient survival through the application of cutting-edge genetic research. As she continues to advance in her career, Alizadeh’s contributions will undoubtedly shape the future of cancer treatment and classification, marking her as a key innovator in her field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…